Product Information
FOSAPREPITANT 150 MG VIAL is a generic product labeled by Baxter Healthcare Corporation, priced at $38.5080 per EA under NDC 00338000801. Its NADAC has been published 13 times since Aug 21, 2024.
Strength
150 mg/5mL
Manufacturer
Baxter Healthcare CorporationNDC
00338000801
Classification
Generic
Dosage Form
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Route
INTRAVENOUS
Last Updated
8/21/2024
Active Ingredients
FOSAPREPITANT DIMEGLUMINEApproval Type
Generic (ANDA)
FDA Application
ANDA211860On Market Since
9/5/2019
Pharmacological Classes
Price Statistics
The NADAC for FOSAPREPITANT 150 MG VIAL has been published 13 times since Aug 21, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $38.5080 per EA |
|---|---|
| All-time high | $38.5080 (Nov 13, 2024) |
| All-time low | $38.5080 (Aug 21, 2024) |
| Median price | $38.5080 |
| Average price | $38.5080 |
| Largest weekly change | 0.0% (Aug 28, 2024) |
| Weeks tracked | 13 |
| Tracking since | Aug 21, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient, strength, and dosage form. Compare the broader picture on the Fosaprepitant Dimeglumine market page.
Lowest-Cost Alternatives
No alternatives available
Frequently asked questions
What is the NADAC price of FOSAPREPITANT 150 MG VIAL?
The current National Average Drug Acquisition Cost (NADAC) for FOSAPREPITANT 150 MG VIAL, manufactured by Baxter Healthcare Corporation, is $38.5080 per EA (NDC 00338000801), effective Nov 13, 2024.
How has the price of FOSAPREPITANT 150 MG VIAL changed over time?
Over the history we have for it, the NADAC for FOSAPREPITANT 150 MG VIAL has held within roughly two percent of its current level. It has been tracked across 13 weekly CMS publications since Aug 21, 2024.
What are the highest and lowest recorded NADAC prices for FOSAPREPITANT 150 MG VIAL?
Since Aug 21, 2024, the NADAC for FOSAPREPITANT 150 MG VIAL has ranged from a low of $38.5080 (Aug 21, 2024) to a high of $38.5080 (Nov 13, 2024), with a median of $38.5080 per EA.
Are there cheaper alternatives to FOSAPREPITANT 150 MG VIAL?
No other NADAC-published product currently shares the active ingredient, strength, and dosage form of FOSAPREPITANT 150 MG VIAL, so no direct lower-cost alternative is listed.
Who manufactures FOSAPREPITANT 150 MG VIAL?
FOSAPREPITANT 150 MG VIAL (NDC 00338000801) is labeled by Baxter Healthcare Corporation, and CMS classifies it as a generic product.
Related Drugs
Same classification